Whenever I deem a case of viral conjunctivitis to be significant enough to warrant the prescription of a topical steroid, I have a very brief discussion with the patient beforehand.
The Diabetic Retinopathy Clinical Research Network (DRCR.net) supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders
Despite the advancement in diagnostic technology and treatment strategies, diabetic retinopathy remains a major cause of new onset blindness in the U.S.
An increasing number of patients diagnosed with diabetes are being prescribed insulin therapy.1
The human microbiome refers to a diverse biological ecosystem of microorganisms residing within—and on the surface of—human beings.
The time to refer patients with diabetic retinopathy (DR) or diabetic macular edema (DME) depends on disease staging and location, especially now that ODs have new treatment options for lessening disease severity.
A 68-year-old black male patient with diabetes was referred from his primary-care physician for evaluation of reduced vision involving the right eye more than the left eye.
The U.S. Food and Drug Administration (FDA) in April 2018 gave its first approval of an artificial intelligence (AI) algorithm for the detection of diabetic retinopathy (DR) in the offices of non-ophthalmic healthcare practitioners.1
Non-eyecare practitioners will be screening your patients for diabetic retinopathy. Find out why this can help or hurt your patients and how you can help guide the process.